Science ❯ Biotechnology

Immunology

Vaccine Research Allergen Research Antibody Research Inflammation Cell Therapy Immune Response Antibody Engineering Cancer Immunotherapy Toll-like Receptors

Biogen Licenses Vanqua’s Preclinical C5aR1 Drug in Deal Worth Up to $1.06 Billion

The company is targeting an FDA IND in 2027 contingent on supportive preclinical data.

Intranasal Antibody Cuts Mugwort Allergy in Mice, Paving Way for Human Trials

Leukemia-on-a-Chip Enables Rapid, Scalable CAR T-Cell Therapy Screening